MagnetisMM-4: Umbrella Study of Elranatamab (PF-06863135) in Combination With Anti-Cancer Treatments in Multiple Myeloma

Description

The purpose of this study is to determine the Recommended Phase 2 Dose and clinical benefit of elranatamab in combination with other anti-cancer therapies in participants with multiple myeloma.

Conditions

Multiple Myeloma

Talk to us

Study Overview

On this page

Study Details

Study overview

The purpose of this study is to determine the Recommended Phase 2 Dose and clinical benefit of elranatamab in combination with other anti-cancer therapies in participants with multiple myeloma.

A PHASE 1B/2, OPEN LABEL UMBRELLA STUDY OF ELRANATAMAB (PF-06863135), A B-CELL MATURATION ANTIGEN (BCMA) CD3 BISPECIFIC ANTIBODY, IN COMBINATION WITH OTHER ANTI-CANCER TREATMENTS IN PARTICIPANTS WITH MULTIPLE MYELOMA

MagnetisMM-4: Umbrella Study of Elranatamab (PF-06863135) in Combination With Anti-Cancer Treatments in Multiple Myeloma

Condition
Multiple Myeloma
Intervention / Treatment

-

Contacts and Locations

Gilbert

Banner Gateway Medical Center, Gilbert, Arizona, United States, 85234

Gilbert

Banner MD Anderson Cancer Center, Gilbert, Arizona, United States, 85234

Little Rock

University of Arkansas for Medical Sciences - Winthrop P. Rockefeller Cancer Institute, Little Rock, Arkansas, United States, 72205

Beverly Hills

Beverly Hills Cancer Center, Beverly Hills, California, United States, 90211

Los Angeles

Cedars Sinai Medical Center Oncology IDS Pharmacy Attn:Suwicha Limvorasak ,PharmaD, Los Angeles, California, United States, 90048

Los Angeles

Cedars Sinai Medical Center, Los Angeles, California, United States, 90048

Los Angeles

Cedars-Sinai Medical Center, Samuel Oschin Comprehensive Cancer Institute (SOCCI), Los Angeles, California, United States, 90048

Tarzana

Cedars-Sinai Tarzana, Tarzana, California, United States, 91356

Coral Gables

Sylvester Comprehensive Cancer Center - The Lennar Foundation Medical Center, Coral Gables, Florida, United States, 33146

Deerfield Beach

Sylvester Comprehensive Cancer Center- Deerfield Beach, Deerfield Beach, Florida, United States, 33442

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Relapsed/refractory multiple myeloma with at least 3 prior lines of therapy
  • * Refractory to at least one IMiD, one proteasome inhibitor, and one anti-CD38 antibody
  • * Measurable disease defined by at least one of the following:
  • 1. Serum M-protein \>/= 0.5 g/dL by SPEP
  • 2. Urinary M-protein excretion \>/= 200 mg/24 hours by UPEP
  • 3. Serum immunoglobulin FLC \>/= 10 mg/dL (\>/= 100 mg/L) AND abnormal serum immunoglobulin kappa to lambda FLC ratio
  • * ECOG performance status 0 -1
  • * Resolved acute effects of any prior therapy to baseline severity or CTCAE Grade \</= 1
  • * Active plasma cell leukemia
  • * Amyloidosis
  • * Stem cell transplant with 12 weeks prior to enrollment, or active GVHD
  • * POEMS syndrome
  • * Any active uncontrolled bacterial, fungal, or viral infection
  • * Impaired cardiovascular function or clinically significant cardiovascular diseases within 6 months prior to enrollment
  • * Previous administration with an investigational drug within 30 days or 5 half-lives preceding the first dose of study treatment (whichever is longer)
  • * Sub-Study A Only: Previous treatment with BCMA bispecific antibody
  • * Sub-Study B Only: Previous treatment with BCMA directed therapy

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Pfizer,

Pfizer CT.gov Call Center, STUDY_DIRECTOR, Pfizer

Study Record Dates

2027-07-31